Sleep diagnostics — polysomnography, home sleep apnea testing, actigraphy, and emerging continuous sleep monitoring — represent a major neurodiagnostics market segment driven by the enormous undiagnosed sleep apnea burden and growing sleep health awareness, with the Neurodiagnostics Market reflecting sleep diagnostics as one of the largest neurodiagnostic market categories.

Home sleep apnea test expansion — the reimbursement-driven shift from in-laboratory polysomnography toward portable home sleep testing for suspected obstructive sleep apnea diagnosis — has created a large commercial home sleep testing market. Companies including WatchPAT (Itamar Medical), Nox T3, ResMed ApneaLink Air, and numerous FDA-cleared home sleep testing devices provide the diagnostic capability that CMS and commercial insurer coverage for home sleep testing has made the default first-line sleep apnea diagnostic approach for uncomplicated OSA suspects.

Continuous positive airway pressure therapy monitoring neurodiagnostics — the built-in CPAP compliance monitoring from ResMed myAir and Philips DreamMapper providing objective CPAP usage data, residual AHI, and mask leak analysis that remote monitoring enables — represents the post-diagnostic sleep monitoring market that treatment compliance documentation requires for insurance continuation coverage. ResMed's AirSense 10 and AirSense 11 connected CPAP platforms generate the adherence data that payors require for continued CPAP supply coverage.

Insomnia sleep diagnostics — the quantitative tools for characterizing insomnia severity (ISI, PSQI validated questionnaires), objective actigraphy-based sleep pattern documentation, and advanced sleep staging devices distinguishing insomnia phenotypes — represent the non-apnea sleep diagnostics market supporting CBT-I and pharmaceutical insomnia treatment decisions. Philips Respironics Actiwatch, ActiGraph, and consumer actigraphy devices provide the objective sleep-wake pattern documentation that sleep clinicians use for insomnia characterization and treatment planning.

Do you think home sleep apnea testing has improved diagnostic access for patients, or has the shift away from in-laboratory PSG resulted in underdiagnosis of more complex sleep disorders in patients presenting with apparent simple OSA?

FAQ

What is polysomnography and what does it diagnose? Polysomnography (PSG) is a comprehensive overnight sleep study measuring EEG (sleep staging), EOG (eye movements for REM identification), EMG (chin and limb muscle activity), airflow, respiratory effort, oxygen saturation, EKG, and body position; PSG diagnoses: sleep apnea (obstructive, central, complex), narcolepsy with cataplexy, REM sleep behavior disorder, periodic limb movement disorder, parasomnias, and sleep-related seizures; in-laboratory PSG provides higher diagnostic accuracy than home tests but costs five hundred to three thousand dollars versus one hundred fifty to four hundred dollars for home tests.

What is a home sleep apnea test? Home sleep apnea tests (HSAT) are portable devices worn at home measuring airflow, oxygen saturation, respiratory effort, and heart rate to diagnose obstructive sleep apnea; HSATs do not include EEG so cannot stage sleep or diagnose non-respiratory sleep disorders; FDA-cleared HSAT devices include WatchPAT One (peripheral arterial tone), Nox T3 (thoracic effort), and multiple oximeter-based systems; CMS covers HSAT for suspected uncomplicated OSA; HSAT has lower sensitivity than PSG (may underestimate OSA severity) but provides adequate diagnosis for most uncomplicated suspected OSA patients.

#Neurodiagnostics #SleepDiagnostics #Polysomnography #HomeSleepTest #SleepApneaDiagnosis #SleepNeurodiagnostics